Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rumona Dickson

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Patient Education and Counseling|July 24, 2002
The most effective psychologically-based treatments to reduce anxiety and panic in patients with chronic obstructive pulmonary disease (COPD): a systematic reviewChristine Rose, Louise Wallace, Rumona Dickson, et al.
BMJ Open|February 10, 2012
A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal processEva C Kaltenthaler, Rumona Dickson, Angela Boland, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2015
Differences in cancer drug assessment between Spain and the United KingdomAna Lozano-Blázquez, Rumona Dickson, María-Dolores Fraga-Fuentes, et al.
Health Technology Assessment (Winchester, England)|June 27, 2020
Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluationJuliet Hounsome, Gerlinde Pilkington, James Mahon, et al.
Systematic Reviews|December 30, 2017
Use of programme theory to understand the differential effects of interventions across socio-economic groups in systematic reviews-a systematic methodology reviewMichelle Maden, Alex Cunliffe, Naoimh McMahon, et al.
Pharmacoeconomics|May 15, 2010
Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisalAdrian Bagust, Janette Greenhalgh, Angela Boland, et al.
Pharmacoeconomics|October 12, 2013
Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisalSophie Beale, Rumona Dickson, Adrian Bagust, et al.
Health Technology Assessment (Winchester, England)|June 27, 2014
Allopurinol for the treatment of chronic kidney disease: a systematic reviewNigel Fleeman, Gerlinde Pilkington, Yenal Dundar, et al.
Pharmacoeconomics|April 24, 2015
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group PerspectiveNigel Fleeman, Adrian Bagust, Sophie Beale, et al.
Pharmacoeconomics|October 5, 2011
Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisalRumona Dickson, Adrian Bagust, Angela Boland, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Patient Education and Counseling|July 24, 2002
The most effective psychologically-based treatments to reduce anxiety and panic in patients with chronic obstructive pulmonary disease (COPD): a systematic reviewChristine Rose, Louise Wallace, Rumona Dickson, et al.
BMJ Open|February 10, 2012
A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal processEva C Kaltenthaler, Rumona Dickson, Angela Boland, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2015
Differences in cancer drug assessment between Spain and the United KingdomAna Lozano-Blázquez, Rumona Dickson, María-Dolores Fraga-Fuentes, et al.
Health Technology Assessment (Winchester, England)|June 27, 2020
Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluationJuliet Hounsome, Gerlinde Pilkington, James Mahon, et al.
Systematic Reviews|December 30, 2017
Use of programme theory to understand the differential effects of interventions across socio-economic groups in systematic reviews-a systematic methodology reviewMichelle Maden, Alex Cunliffe, Naoimh McMahon, et al.
Pharmacoeconomics|May 15, 2010
Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisalAdrian Bagust, Janette Greenhalgh, Angela Boland, et al.
Pharmacoeconomics|October 12, 2013
Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisalSophie Beale, Rumona Dickson, Adrian Bagust, et al.
Health Technology Assessment (Winchester, England)|June 27, 2014
Allopurinol for the treatment of chronic kidney disease: a systematic reviewNigel Fleeman, Gerlinde Pilkington, Yenal Dundar, et al.
Pharmacoeconomics|April 24, 2015
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group PerspectiveNigel Fleeman, Adrian Bagust, Sophie Beale, et al.
Pharmacoeconomics|October 5, 2011
Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisalRumona Dickson, Adrian Bagust, Angela Boland, et al.
Pageof 4